# A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus

> **NCT07299084** · PHASE1 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 40 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2
- Overweight
- Obesity

## Interventions

- **DRUG:** Tirzepatide

## Key facts

- **NCT ID:** NCT07299084
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-14
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07299084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07299084, "A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07299084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*